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Summary
Molybdenum cofactor deficiency (MoCoD) is a fatal dis-
order manifesting, shortly after birth, with profound
neurological abnormalities, mental retardation, and se-
vere seizures unresponsive to any therapy. The disease
is a monogenic, autosomal recessive disorder, and the
existence of at least two complementation groups sug-
gests genetic heterogeneity. In humans, MoCoD leads to
the combined deficient activities of sulfite oxidase, xan-
thine dehydrogenase, and aldehyde oxidase. By using
homozygosity mapping and two consanguineous af-
fected kindreds of Israeli-Arab origin, including five pa-
tients, we demonstrated linkage of a MoCoD gene to
an 8-cM region on chromosome 6p21.3, between mark-
ers D6S1641 and D6S1672. Linkage analysis generated
the highest combined LOD-score value, 3.6, at a recom-
bination fraction of 0, with marker D6S1575. These
results now can be used to perform prenatal diagnosis
with microsatellite markers. They also provide the only
tool for carrier detection of this fatal disorder.
Introduction
Molybdenum cofactor deficiency (MoCoD; MIM
252150 and 252160) is a fatal inherited disorder man-
ifesting shortly after birth and resulting from the absence
of a molybdenum-complexed pterin cofactor (Johnson
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et al. 1980). The most noted clinical features are neo-
natal seizures unresponsive to any therapy; abnormal
tone and opisthotonos; mental retardation; cranofacial
dysmorphic features, including narrow bifrontal diam-
eter and enophthalmos; ectopia lentis; and neurological
deterioration (Slot et al. 1993). No treatment has been
successful in halting or reversing the progression of neu-
rological damage (Johnson and Wadman 1995). Bio-
chemically, MoCoD is caused by defects in the biosyn-
thesis of the molybdenum-complexed pterin that is the
cofactor for three enzymes: sulfite oxidase, xanthine de-
hydrogenase, and aldehyde oxidase. Sulfate oxidase de-
ficiency causes accumulation of sulfite, taurine, S-sul-
focysteine, and thiosulfate in the urine, and deficiency
of xanthine dehydrogenase causes xanthinuria and hy-
pouricemia. The pathogenesis of the clinical features is
not understood, but, because this clinical pattern is sim-
ilar to that seen in isolated sulfite oxidase deficiency, the
pathogenesis has been assumed to be related to an ac-
cumulation of sulfite metabolites or to a need, by the
developing brain, for this enzyme or its product (Johnson
and Wadman 1995). Prenatal diagnosis is determined by
demonstration of either sulfite oxidase deficiency in cho-
rionic villus direct preparations or increased S-sulfocy-
steine in amniotic fluid (Gray et al. 1990; Johnson et al.
1991b). Postnatal diagnosis is suggested by hypouri-
cemia and the finding of elevated urinary metabolites,
as described above (van Gennip 1987), and is confirmed
by demonstration of sulfite oxidase deficiency in
fibroblasts.
The disease is a monogenic, autosomal recessive dis-
order. The existence of complementation groups type A
(MIM 252150) and type B (MIM 252160), observed in
patients’ fibroblasts (Johnson et al. 1989), suggests the
possibility of multiple genetic variants of MoCoD.
Thus far, MoCoD has been reported to be present in
150 families belonging to various ethnic groups (Arnold
et al. 1993; Johnson et al. 1993; van Gennip et al. 1994;
Mize et al. 1995; Bonioli et al. 1996; Yurdakok and
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Coskun 1997). For this study, we conducted a full ge-
nome search, using polymorphic microsatellite markers
in two MoCoD-affected inbred kindreds of Arab-Israeli
origin. One of these kindreds was very large and in-
cluded eight subfamilies. Using homozygosity mapping,
we found genetic linkage between MoCoD and several
markers in an 8-cM region on chromosome 6p21.3.
Subjects and Methods
Families and DNA Preparation
Two unrelated Arab-Israeli consanguineous MoCoD
kindreds were included in the study. The pedigrees of
the two kindreds are shown in figure 1. These families
live in two close villages in northern Israel. Kindred 1
consisted of eight subfamilies, with a total of 18 affected
children. Among the 18 affected children, we had access
to DNA samples from 4 patients (5102, 5104, 6101,
and 5140). In this kindred, the first MoCoD patient
(5140) was diagnosed in 1993 (van Gennip et al. 1994).
The construction of a detailed pedigree of kindred 1
disclosed 14 additional patients (including several sib-
lings of MoCoD patients), who had died undiagnosed
during the 5 years prior to the study. A review of the
medical files and autopsy reports strongly suggested that
these infants suffered fromMoCoD. Note that, since the
first MoCoD patient was diagnosed, three additional
affected babies (5104, 5102, and 6101) from this kin-
dred were born to young first-cousin parents. Kindred
2 consisted of two deceased patients (64 and 65). The
first patient died undiagnosed, but her medical history
supported diagnosis of MoCoD. The second patient (65)
was born and diagnosed in 1994. We only had access
to a DNA sample from patient 65. In the two families,
the diagnosis of MoCoD was based on clinical symp-
toms that appeared shortly after birth (mainly, neonatal
seizures unresponsive to any therapy, opisthotonos, and
facial dysmorphism), a biochemical finding of hypour-
icemia and abnormal sulfur and purine metabolites in
urine, and the detection of sulfite oxidase deficiency in
fibroblasts. The clinical features of patients of both fam-
ilies were similar, except for the hypertonicity and op-
isthotonos, which were more pronounced in the patients
from kindred 2. Obligate-heterozygous parents did not
display any symptoms. EDTA blood samples for genetic
analysis were collected from each living family member,
after informed consent was obtained from the subjects
or their guardians, in accordance with the guidelines of
the local institutions. DNAwas obtained from fibroblast
cell lines, for patients 5140, 5104, and 65, and from
EDTA blood samples, for patients 6102 and 5102. DNA
was prepared by standard methods (Sambrook et al.
1989). Altogether we had access to DNA samples from
5 patients and 24 healthy subjects.
Genotype Analysis
A genomewide screen was performed on an auto-
mated sequencing machine by use of a panel of 240
highly polymorphic microsatellite markers (CA), spaced
at ∼10-cM intervals, chosen from the Ge´ne´thon panel
(Dib et al. 1996). Extended haplotypes were constructed
by use of dinucleotide-repeat markers (CA) in the can-
didate region and the sex-averaged genetic map de-
scribed by Ge´ne´thon (Dib et al. 1996), as shown in figure
2. Genotyping of the markers was performed, by use of
a nonradioactive-labeling procedure, with the ECL sys-
tem (Amersham), on the basis of a horseradish peroxi-
dase–mediated chemiluminescent reaction, in accor-
dance with the study by Gyapay et al. (1996).
Statistical Analysis
Two-point linkage analysis of the disease locus and
the genetic markers was performed by use of theMLINK
program from the FASTLINK optimized version of the
LINKAGE package (Lathrop et al. 1984; Cottingham et
al. 1993; Schaffer et al. 1994). An autosomal recessive
model with complete penetrance for both sexes and a
frequency of .001 for the disease allele was assumed.
Since the allele frequencies of the markers were not
known, for the particular population group of the study,
LOD scores were calculated by assumption of equal al-
lele frequencies. Similar results were obtained when pop-
ulation allele frequencies were estimated from the data
(results not shown).
Results
Primary Mapping of the MoCoD Locus in the Israeli-
Arab Kindreds
A genomewide screen of the two MoCoD-affected
kindreds of Israeli-Arab origin (kindreds 1 and 2; fig. 1)
was performed. Two markers, D6S291 and D6S282, on
chromosome 6 gave positive LOD scores, suggesting
linkage between MoCoD and chromosome 6p, in these
two families. A panel of 13 additional markers were
genotyped in this region. Two-point linkage analysis was
performed. Evidence for linkage to this region was found
in two kindreds. Positive LOD scores were obtained for
all markers tested. Marker D6S1575 gave the highest
combined LOD-score value, 3.6, at a recombination
fraction of 0. These data confirmed linkage of the
MoCoD locus to chromosome 6p in the Israeli-Arab
families.
Haplotype Analysis and Recombination Events in the
Israeli-Arab Kindreds
Extended haplotypes were constructed, by use of the
15 microsatellite markers, for all subjects from consan-
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Figure 2 Haplotype analysis, on chromosome 6p21, of MoCoD kindreds 1 and 2. Only key subjects are shown. Telomeric to centromeric
markers are arranged from top to bottom. The linked haplotype is boxed. The shaded area corresponds to segments of haplotypes shared
between healthy individual 5139 and affected individual 5140. Alleles in parenthesis were inferred. In family 2, marker D6S1562 was technically
unsatisfactory and is not shown.
guineous kindreds 1 and 2. Results are shown in figure
2. As was expected, on the basis of homozygosity by
descent, regions of homozygosity were observed in the
genomes of all affected individuals. Each of the five sub-
jects with MoCoD was homozygous for all loci between
and including D6S1576 and D6S426. Flanking this re-
gion of consistent homozygosity, a heterozygous geno-
type was found at marker D6S1672 for the affected in-
dividual (5104) in subfamily B of kindred 1, thus
defining the centromeric limit of the MoCoD gene in-
terval at this marker. Similarly, the affected individual
(5140) in subfamily D of kindred 1 was found to be
heterozygous at marker D6S291, thus defining the telo-
meric limit of the disease gene interval at this marker.
We were able to replace this limit by the marker
D6S1641. Comparison of the haplotypes of affected in-
dividual 5140 with the haplotypes of healthy sibling
5139, both from subfamily D of kindred 1, showed
one homozygous segment of shared haplotypes, be-
tween D6S291 and D6S1641, and one segment
(D6S1562–D6S282) in which the haplotypes differed as
a result of a recombination event on the paternal chro-
mosome of the healthy individual. This observation en-
abled us to exclude from the MoCoD gene interval the
region above marker D6S1641. Thus, we mapped the
MoCoD locus to be within an 8-cM region extend-
ing between, but excluding, markers D6S1641 and
D6S1672. The disease-associated haplotype in the pa-
tients from kindred 1 was compared with the affected
chromosome in the patients from kindred 2. This com-
parison showed one segment of shared haplotype
(D6S1616–D6S1575) and two segments in which
the haplotypes differed (D6S1576–D6S1607 and
D6S426–D6S282).
Discussion
This is the first linkage study of MoCoD syndrome.
We present evidence that a MoCoD locus maps to chro-
mosome 6p21.3, in an 8-cM interval between D6S1641
and D6S1672. Given the small number of patients avail-
able, this study emphasizes the power of a dense map
of microsatellite markers, combined with homozygosity
mapping of rare recessive disease-causing genes, when
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genetically isolated populations consisting of large con-
sanguineous families are available (Lander and Boistein
1987; Thomas et al. 1995; Neufeld et al. 1997).
Data associating particular alleles of marker loci with
disease-causing mutations are sometimes helpful for the
refined localization of a disease gene. When shared hap-
lotypes are found in patients from the same inbred pop-
ulation, this may provide evidence for a founder effect.
If there is a founder effect within a population, crossover
between the mutation causing the phenotype and closely
situated markers—a phenomenon known as “linkage
disequilibrium”—is often rare. The region of shared
haplotypes in patients from kindreds 1 and 2 may rep-
resent this type of linkage disequilibrium (Hastbacka et
al. 1992; Sirugo et al. 1992). Haplotype analysis of ad-
ditional MoCoD-affected families reported in the liter-
ature may uncover linkage disequilibrium and may nar-
row the critical interval. Furthermore, haplotype
analysis may give us evidence of genetic heterogeneity,
as suggested by the existence of complementation
groups, observed in MoCoD patients’ fibroblasts (John-
son et al. 1989).
Investigation of the molybdenum-cofactor–synthesis
pathway is hampered by the low abundance of the co-
factor in the cells and by its extreme instability in isolated
form. Genes involved in its synthesis are studied best in
eubacteria—namely, Escherichia coli K12, for which
112 different corresponding genes have been identified
and sequenced (Reiss et al. 1987; Nohno et al. 1988;
Johnson et al. 1991a; Rivers et al. 1993; Rech et al.
1995). Three genes have been identified in higher plants
(Hoff et al. 1995; Stallmeyer et al. 1995): one of them
is homologous to the Drosophila gene cinnamon and
the rat protein gephyrin (Prior et al 1992; Kamdar et al.
1994). The other two plant genes show strong homology
to E. coli genes involved in the early steps of synthesis,
and the complementation studies of human fibroblasts
indicate that the majority of MoCoD patients can be
expected to carry lesions in similar genes (Johnson et al.
1989). However, no such “early” genes have been iden-
tified in mammals. The human homologues of these
“early” genes, as well as the human gephyrin gene, are
candidate genes for MoCoD.
We have mapped a MoCoD gene to an 8-cM region
on chromosome 6p21.3. This region contains several
known genes, including the genes for G1/S-specific cyclin
D3, peripherin, and progasticsin precursor, and 140 ex-
pressed sequence tags (see the NCBI-Science Human
Gene Map). However, none of these genes are obvious
candidate genes for MoCoD. This suggests that, once
refined mapping has been accomplished, identification
of the MoCoD gene will require a combination of po-
sitional cloning (Collins 1995) and candidate-gene
approaches.
MoCoD is an incurable disorder. The cofactor itself
is exceedingly unstable. Thus, direct cofactor replace-
ment is not feasible. Various therapeutic trials including
oral intake of molybdenum salts and a low-cysteine diet
combined with oral sulfate supplementation do not re-
sult in any benefit (Munnich et al 1983; Endres et al
1988; Johnson and Wadman 1995). To date, the inci-
dence of this genetic disorder probably is underesti-
mated, because routine metabolic testing may fail to re-
veal the biochemical abnormalities. An enhanced
awareness of this disease and application of the appro-
priate tests could lead to an increase in the rate of de-
tection of patients, which would reflect MoCoD’s true
incidence. An excessive occurrence of this fatal disorder
was observed among segments of the Arab population
in northern Israel. The high incidence probably is due
to the high rate of consanguinity (up to 50%) in this
population (Jaber et al. 1991) and warrants the urgent
development of tools for the detection of carriers, in
order to provide genetic counseling. The immediate ben-
efit of our mapping effort is the ability to perform pre-
natal diagnosis by use of microsatellite markers. This
study also provides a tool for carrier detection of this
incurable disorder.
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